Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

20001,264 citationsJournal Article

Authors

Temozolomide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanced metastatic melanoma.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 18, Issue 1, pp. 158-158

Field-Weighted Citation Impact: 14.04